Veracyte, Inc. (NASDAQ:VCYT) Shares Acquired by Perkins Capital Management Inc.
Veracyte, Inc. (NASDAQ:VCYT) Shares Acquired by Perkins Capital Management Inc.
Perkins Capital Management Inc. lifted its holdings in Veracyte, Inc. (NASDAQ:VCYT – Get Rating) by 4.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 128,130 shares of the biotechnology company's stock after buying an additional 5,150 shares during the period. Veracyte comprises approximately 2.6% of Perkins Capital Management Inc.'s portfolio, making the stock its 9th biggest position. Perkins Capital Management Inc. owned about 0.18% of Veracyte worth $2,550,000 at the end of the most recent quarter.
據美國證券交易委員會的最新披露，珀金斯資本管理公司在第二季度增持了Veracyte公司的股份4.2%。在此期間，該公司又購買了5,150股生物技術公司的股票，目前持有128,130股。Veracyte約佔Perkins Capital Management Inc.投資組合的2.6%，使該股成為其第9大持倉。截至最近一個季度末，Perkins Capital Management Inc.持有Veracyte約0.18%的股份，價值2，55萬美元。
Other hedge funds and other institutional investors have also modified their holdings of the company. ARK Investment Management LLC boosted its position in Veracyte by 1.1% during the second quarter. ARK Investment Management LLC now owns 8,856,245 shares of the biotechnology company's stock valued at $155,693,000 after purchasing an additional 100,221 shares during the last quarter. Invesco Ltd. increased its stake in Veracyte by 0.4% during the first quarter. Invesco Ltd. now owns 4,131,597 shares of the biotechnology company's stock valued at $113,908,000 after acquiring an additional 17,566 shares during the period. State Street Corp increased its stake in Veracyte by 45.5% during the first quarter. State Street Corp now owns 3,945,870 shares of the biotechnology company's stock valued at $108,788,000 after acquiring an additional 1,234,244 shares during the period. Granahan Investment Management LLC increased its stake in Veracyte by 9.3% during the first quarter. Granahan Investment Management LLC now owns 1,960,736 shares of the biotechnology company's stock valued at $54,057,000 after acquiring an additional 166,341 shares during the period. Finally, Champlain Investment Partners LLC increased its stake in Veracyte by 2.9% during the first quarter. Champlain Investment Partners LLC now owns 1,818,305 shares of the biotechnology company's stock valued at $50,131,000 after acquiring an additional 50,805 shares during the period.
其他對衝基金和其他機構投資者也調整了對該公司的持股。Ark Investment Management LLC在第二季度將其在Veracyte的頭寸增加了1.1%。Ark Investment Management LLC現在擁有這家生物技術公司8,856,245股股票，價值155,693,000美元，上個季度又購買了100,221股。景順在第一季度增持了Veracyte 0.4%的股份。景順公司目前持有這家生物技術公司的4,131,597股股票，價值113,908,000美元，在此期間又購入了17,566股。道富集團在第一季度增持了Veracyte 45.5%的股份。道富集團目前持有這家生物技術公司3945,870股股票，價值108,788,000美元，在此期間又收購了1,234,244股。Granahan Investment Management LLC在第一季度將其在Veracyte的持股增加了9.3%。Granahan Investment Management LLC現在擁有這家生物技術公司1,960,736股，價值54,057,000美元，在此期間又購買了166,341股。最後，尚普蘭投資夥伴有限責任公司在第一季度增持了2.9%的Veracyte股份。尚普蘭投資夥伴有限責任公司現在擁有這家生物技術公司1,818,305股股票，價值50,131,000美元，在此期間又購買了50,805股。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Several equities analysts recently issued reports on VCYT shares. Raymond James boosted their price target on Veracyte from $30.00 to $31.00 and gave the company an "outperform" rating in a research note on Thursday, August 4th. StockNews.com assumed coverage on Veracyte in a report on Wednesday. They set a "sell" rating on the stock. Finally, Needham & Company LLC lifted their price objective on Veracyte from $26.00 to $31.00 and gave the company a "buy" rating in a report on Wednesday, August 3rd. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $42.50.
幾位股票分析師最近發佈了關於VCYT股票的報告。雷蒙德·詹姆斯在8月4日週四的一份研究報告中將Veracyte的目標價從30.00美元上調至31.00美元，並給予該公司“跑贏大盤”的評級。StockNews.com在週三的一份報告中對Veracyte進行了報道。他們對該股設定了“賣出”評級。最後，Needham&Company LLC在8月3日星期三的一份報告中將Veracyte的目標價從26.00美元上調至31.00美元，並給予該公司“買入”評級。一名投資分析師對該股的評級為賣出，六名分析師對該公司股票的評級為買入。根據MarketBeat的數據，該股的平均評級為“適度買入”，共識目標價為42.50美元。
Veracyte Price Performance
Veracyte性價比
Veracyte (NASDAQ:VCYT – Get Rating) last announced its earnings results on Tuesday, August 2nd. The biotechnology company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.08. The business had revenue of $72.86 million for the quarter, compared to the consensus estimate of $67.37 million. Veracyte had a negative return on equity of 4.05% and a negative net margin of 18.13%. On average, equities analysts forecast that Veracyte, Inc. will post -0.8 EPS for the current year.
Veracyte(納斯達克代碼：VCyT-GET Rating)上一次公佈財報是在8月2日(星期二)。這家生物技術公司公佈了本季度每股收益(0.13美元)，比普遍預期的(0.21美元)高出0.08美元。該業務本季度的收入為7286萬美元，而普遍預期為6737萬美元。Veracyte的淨資產回報率為負4.05%，淨利潤率為負18.13%。股票分析師平均預測，Veracyte，Inc.本年度每股收益將為0.8%。
Veracyte Profile
Veracyte配置文件
(Get Rating)
(獲取評級)
Veracyte, Inc operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis.
Veracyte，Inc.是一家全球性的診斷公司。該公司提供Afirma基因組測序分類器和Xpression Atlas，用於確定結果不確定的患者是否為良性疾病，以避免不必要的手術；解密前列腺癌活檢和根治性前列腺癌切除術；Prosigna乳腺癌檢測用於乳腺癌診斷；Percepta基因組測序分類器和Percepta鼻拭子測試用於肺癌診斷；Envisia基因組分類器用於診斷間質性肺部疾病，包括特發性肺纖維化；免疫結腸癌檢測用於結腸癌診斷。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Veracyte (VCYT)
- Constellation Brands Stock May Offer Safety in the Market Storm
- Domino's Pizza Rises To The Occasion In Q3
- O'Reilly & AutoZone Outperform The S&P: Is Either A Better Stock?
- Amgen Shares Leap Higher On Upbeat Outlook For Obesity Treatment
- Three Dividend Growers the Institutions Are Buying
- 免費獲取StockNews.com關於Veracyte的研究報告(VCyT)
- 星座品牌股票可能在市場風暴中提供安全
- 多米諾披薩在第三季度應運而生
- O‘Reilly&AutoZone的表現好於標準普爾指數：哪隻股票更好？
- 安進股價跳漲，肥胖治療前景樂觀
- 這些機構正在收購的三家股息增長公司
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.
接受Veracyte Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Veracyte和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。